The KDIGO 2026 Clinical Practice Guideline for Diabetes and Chronic Kidney Disease (CKD) is available for public review through April 13, 2026. We invite you to review the draft and share comments to help inform the final guideline. You can download the public review draft and share comments via the feedback form below and on the KDIGO Diabetes and CKD Guideline website.

This update incorporates significant clinical and scientific developments that have emerged since the KDIGO 2022 Diabetes Guideline. It is specifically focused on three main areas: a new Chapter 1 covering definitions, prevention, and risk assessment, Chapter 2 related to glycemic monitoring, and Chapter 4 addressing comprehensive pharmacotherapy.

The update process utilized a rigorous evidence-based framework, including systematic reviews of studies published through July 2025, assessment of the certainty of evidence and the strength of each recommendation using the GRADE approach, and alignment of the new data with modern treatment strategies for managing diabetes in patients with CKD.

We recognize that your time is limited, so you are welcome to focus your review on the sections most relevant to your expertise. All comments are appreciated. By submitting comments, you agree that KDIGO may acknowledge your contribution as a reviewer in the final publication.

Visit the KDIGO Diabetes and CKD Guideline website to download the public review draft and data supplement, and submit comments via the feedback form.